AlphAIAlphAI — Financial news for AI agents
investing.com$MRNA

Moderna earnings beat by $1.47, revenue fell short of estimates

Moderna (MRNA) reported Q3 EPS of $0.38, beating estimates by $1.47, but revenue of $1.31M fell short of expectations. The stock is up 303.71% in the last 3 months and 883.94% in the last 12 months. InvestingPro rates its financial health as 'good performance'.

Original reporting
investing.com
Published Nov 6, 2026, 12:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MRNA
Bullish
high confidence
Mentioned
$MRNA
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The earnings surprise is likely to drive short‑term buying pressure, especially in after‑hours trading, and could boost the broader biotech sector.

02

Market read

A large‑cap biotech earnings beat can influence sector sentiment and attract capital flows into related stocks.

03

What to watch

Potential upcoming regulatory scrutiny or competition in mRNA space could temper upside.

Relevance 9/10Novelty 9/10Timing: after-hours reaction

Background

Moderna's Q3 earnings were released on Nov 6, 2026, with a notable EPS beat and revenue beat versus consensus estimates.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna reported Q3 EPS of $0.38, beating estimates by $1.47 and revenue of $1.31B vs $892M consensus.

Expected impact

upward pressure as investors price in better-than-expected earnings.

Evidence & confidence

The sizable EPS beat and revenue beat for a large‑cap biotech typically trigger a positive price reaction, especially after market close.

Market effects

Sector

Biotech sector may see a rally as Moderna's results lift sentiment on mRNA therapeutics.

Regional

U.S. markets could open higher on biotech gains.

Global

Global investors tracking vaccine and therapeutic pipelines may adjust exposure.

Counterpoint

What could challenge this read

Some investors may view the revenue beat as modest and worry about future pipeline risk, suggesting caution.

Key entities

  • company
    Moderna

    Biotech firm developing mRNA vaccines and therapeutics.

Read at source← All news

StoryModerna posts Q3 profit, beats revenue estimates and lifts 2026 growth outlook

Also covered by

5 outlets

Related articles

$MRNAHighAI 9/10

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna (MRNA) reported Q3 2026 EPS of $0.38, beating estimates by $1.48. Revenue rose 29.2% YoY to $1.31B, driven by international COVID-19 vaccine sales. The company raised its 2026 sales outlook to 15-25% growth and reduced R&D spending plans. Shares rose in pre-market trading. Key products include mFlusiva and mCoflu vaccines, with mixed pipeline results.

zacks.com
$MRNAMedAI 8/10

WHO adds two more Ebola vaccines to clinical trial

WHO adds two Ebola vaccines, ChAdOx1 and mRNA-1469, to clinical trial in DRC. Developed by Oxford/Serum Institute and Moderna, they target the Bundibugyo virus. WHO's advisory group recommended further evaluation. Trial led by Institut National de Recherche Biomédicale and others. Current outbreak has caused over 4,600 cases and 2,100 deaths.

finance.yahoo.com
$MRNAMedAI 8/10

Moderna enjoys stable vaccine sales thanks to global COVID uptake

Moderna reported a 29% revenue increase to $1.3 billion for the quarter, driven by global COVID-19 vaccine sales. CFO Jamey Mock attributed growth to higher uptake of mNEXSPIKE and Spikevax. U.S. revenue is declining, but global expansion is leading sales. Moderna raised annual revenue expectations to 15-25%. Analysts noted strong vaccine sales and potential market share gains in the EU post-Pfizer's contract expiration.

biospace.com
$MRNAHighAI 8/10

What Moderna (MRNA) Said on Its Q3 Earnings Call

Moderna reported a 27% drop in R&D expenses to $583M in Q3, while SG&A expenses rose 5% to $282M. The company reduced its full-year R&D and capital expenditure estimates. Cash and investments increased to $8B. Moderna expects year-end cash of $8.1B-$8.3B. It announced progress in melanoma, renal cell carcinoma, and pancreatic cancer studies, and received FDA approval for its flu vaccine mFLUSIVA. The norovirus vaccine candidate did not meet interim success criteria.

finance.yahoo.com